Table 3.
Shift table for added antihypertensive treatment at baseline and for cumulative changes at the last documented visit (safety population)
Olmesartan-amlodipine 20/5 mg at last documented visit |
Olmesartan-amlodipine 40/5 mg at last documented visit |
Olmesartan-amlodipine 40/10 mg at last documented visit |
Total (baseline)* |
|||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | |
Olmesartan-amlodipine 20/5 mg at baseline | 2877 | 37.0 | 817 | 10.5 | 301 | 3.8 | 3955 | 51.4 |
Olmesartan-amlodipine 40/5 mg at baseline | 132 | 1.7 | 1736 | 22.3 | 538 | 6.9 | 2406 | 31.0 |
Olmesartan-amlodipine 40/10 mg at baseline | 50 | 0.6 | 77 | 0.9 | 1233 | 15.8 | 1360 | 17.5 |
Total (follow-up) | 3059 | 39.4 | 2630 | 33.8 | 2072 | 26.6 |
Note:
Add up to 99.9% because of rounding.